Loading…
Reported covered position: Senate Committee on Health, Education, Labor and Pensions, Oversight & Investigations Law Clerk (May-July 2016, August-December 2017)
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2026 · third_quarter · Q3
Real-world health data and analytics policy; Legislative Discussion Draft of the Next-Generation U.S. Clinical Development to Accelerate Cures Proposal.
Real-world health data and analytics policy; Legislative Discussion Draft of the Next-Generation U.S. Clinical Development to Accelerate Cures Proposal.
Filing targets: HOUSE OF REPRESENTATIVES
Source: Senate LDA
| PROCARE SOFTWARE, LLC |
| 2 |
| 2021 |
| CHANEL, INC. | 1 | 2019 |
| MAJOR LEAGUE SOCCER, LLC (MLS) | 1 | 2020 |
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708) *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent Eligibility Restoration Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708) *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
RESTORE Patent Rights Act of 2025
Client: QUALCOMM INCORPORATED · Firm: COVINGTON & BURLING LLP
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Consolidated Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Consolidated Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; H.R. 4511, FDA Advancing Collection of Transformative Science (FACTS) Act; S. 1508, A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; H.R. 4511, FDA Advancing Collection of Transformative Science (FACTS) Act; S. 1508, A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; H.R. 4511, FDA Advancing Collection of Transformative Science (FACTS) Act; S. 1508, A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
Client: RWE ALLIANCE INC. · Firm: COVINGTON & BURLING LLP
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; H.R. 4511, FDA Advancing Collection of Transformative Science (FACTS) Act; S. 1508, A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
Fairness for High-Skilled Immigrants Act of 2019
Client: MAJOR LEAGUE SOCCER, LLC (MLS) · Firm: COVINGTON & BURLING LLP
United States employment visa policy; S. 386, the Fairness for High-Skilled Immigrants Act of 2019; S. Res. 461, A resolution congratulating Seattle Sounders FC on winning the 2019 Major League Soccer Cup
Fairness for High-Skilled Immigrants Act of 2019
Client: MAJOR LEAGUE SOCCER, LLC (MLS) · Firm: COVINGTON & BURLING LLP
United States employment visa policy; S. 386, the Fairness for High-Skilled Immigrants Act of 2019
A resolution congratulating Seattle Sounders FC on winning the 2019 Major League Soccer Cup.
Client: MAJOR LEAGUE SOCCER, LLC (MLS) · Firm: COVINGTON & BURLING LLP
United States employment visa policy; S. 386, the Fairness for High-Skilled Immigrants Act of 2019; S. Res. 461, A resolution congratulating Seattle Sounders FC on winning the 2019 Major League Soccer Cup
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2026 · third_quarter · Q3
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA); Trade and intellectual property issues.
Education concerning wireless foundational technologies; Innovation issues.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539).
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2026 · third_quarter · Q3
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2026 · second_quarter · Q2
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA); Trade and intellectual property issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning wireless foundational technologies; Innovation issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2026 · second_quarter · Q2
Multiemployer pension issues. *ONLY WILLIAM WICHTERMAN LOBBIED THE DEPARTMENT OF LABOR.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), Pension Benefit Guaranty Corporation (PBGC), SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2026 · second_quarter · Q2
Real-world health data and analytics policy; Legislative Discussion Draft of the Next-Generation U.S. Clinical Development to Accelerate Cures Proposal.
Real-world health data and analytics policy; Legislative Discussion Draft of the Next-Generation U.S. Clinical Development to Accelerate Cures Proposal.
Filing targets: HOUSE OF REPRESENTATIVES
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2026 · first_quarter · Q1
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES, Labor, Dept of (DOL), SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2026 · first_quarter · Q1
Education concerning wireless foundational technologies; Innovation issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA); Trade and intellectual property issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2025 · fourth_quarter · Q4
Education concerning wireless foundational technologies; Innovation issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA); Trade and intellectual property issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2025 · fourth_quarter · Q4
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES, Pension Benefit Guaranty Corporation (PBGC)
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2025 · third_quarter · Q3
Education concerning wireless foundational technologies; Innovation issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA); Trade and intellectual property issues. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2025 · third_quarter · Q3
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2025 · third_quarter · Q3
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Filing targets: Food & Drug Administration (FDA)
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2025 · second_quarter · Q2
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708); PREVAIL Act (S. 1553, H.R. 3160); Patent Eligibility Restoration Act (S. 1546, H.R. 3152); Leadership in CET Act (S. 1833, H.R. 3539). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning wireless foundational technologies; Innovation issues; Connected Vehicle legislation; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2025 · second_quarter · Q2
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES, Pension Benefit Guaranty Corporation (PBGC), SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2025 · second_quarter · Q2
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2025 · first_quarter · Q1
Patent legislation generally; Intellectual property/antitrust issues; RESTORE Patent Rights Act of 2025 (H.R. 1574, S. 708) *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning wireless foundational technologies; Innovation issues; Connected Vehicle legislation; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2025 · first_quarter · Q1
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES, Pension Benefit Guaranty Corporation (PBGC), SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2025 · first_quarter · Q1
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Filing targets: SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2024 · fourth_quarter · Q4
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning 5G wireless foundational technologies; Innovation issues. Connected Vehicle legislation; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2024 · fourth_quarter · Q4
Multiemployer pension issues.
Filing targets: Pension Benefit Guaranty Corporation (PBGC)
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2024 · fourth_quarter · Q4
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2024 · third_quarter · Q3
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning 5G wireless foundational technologies; Innovation issues. Connected Vehicle legislation; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2024 · third_quarter · Q3
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2024 · first_quarter · 1A
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning 5G wireless foundational technologies; Innovation issues. Research Advancing to Market Production (RAMP) for Innovators Act; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2024 · third_quarter · Q3
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Filing targets: HOUSE OF REPRESENTATIVES
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2024 · second_quarter · Q2
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Export/Trade Controls; Outbound investment issues; National Defense Authorization Act (NDAA). *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning 5G wireless foundational technologies; Innovation issues. Research Advancing to Market Production (RAMP) for Innovators Act; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2024 · second_quarter · Q2
Multiemployer pension issues.
Filing targets: HOUSE OF REPRESENTATIVES, Pension Benefit Guaranty Corporation (PBGC), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2024 · first_quarter · 1A
Multiemployer pension funding legislation.
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2024 · second_quarter · Q2
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2024 · first_quarter · Q1
Multiemployer pension funding legislation.
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2024 · first_quarter · Q1
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Education concerning 5G wireless foundational technologies; Innovation issues. Research Advancing to Market Production (RAMP) for Innovators Act; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE UNTIL AFTER 3/09/24.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, U.S. Copyright Office
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2024 · first_quarter · Q1
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2023 · fourth_quarter · Q4
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE.
Education concerning 5G wireless foundational technologies; Innovation issues. Research Advancing to Market Production (RAMP) for Innovators Act; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2023 · fourth_quarter · Q4
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2023 · fourth_quarter · Q4
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2023 · third_quarter · Q3
Education concerning 5G wireless foundational technologies; Innovation issues. Research Advancing to Market Production (RAMP) for Innovators Act; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE.
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE.
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2023 · third_quarter · Q3
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Real-world health data and analytics policy.
Filing targets: SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2023 · second_quarter · Q2
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE.
Education concerning 5G wireless foundational technologies; Innovation issues. Research Advancing to Market Production (RAMP) for Innovators Act; Artificial Intelligence legislation. *MATTHEW SHAPANKA DID NOT LOBBY THE SENATE.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2023 · second_quarter · Q2
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2023 · second_quarter · Q2
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
Filing targets: SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2023 · first_quarter · Q1
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2023 · first_quarter · Q1
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2023 · first_quarter · Q1
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2022 · fourth_quarter · Q4
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA); The Unleashing American Innovators Act; Restoring the America Invents Act; Pride in Patent Ownership Act.
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA)
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Multiemployer pension funding legislation.
Filing targets: SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA); The Unleashing American Innovators Act; Restoring the America Invents Act; Pride in Patent Ownership Act.
Education concerning 5G wireless foundational technologies; Innovation issues; CHIPS and Science Act; Research Advancing to Market Production (RAMP) for Innovators Act; National Defense Authorization Act (NDAA).
Filing targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Patent & Trademark Office (PTO), SENATE, Small Business Administration (SBA), State, Dept of (DOS), U.S. Trade Representative (USTR)
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2022 · third_quarter · Q3
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Pension Benefit Guaranty Corporation (PBGC), SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA); The Unleashing American Innovators Act; Restoring the America Invents Act; Pride in Patent Ownership Act.
Education concerning 5G wireless foundational technologies; Technology standards governance legislation; Innovation issues; United States Innovation and Competition Act (USICA); National Science Foundation (NSF) for the Future Act; National Science and Technology Strategy Act; Research Advancing to Market Production (RAMP) for Innovators Act.; National Defense Authorization Act (NDAA); Connected and Automated Vehicle Policy; America COMPETES Act.
Filing targets: Defense, Dept of (DOD), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Institute of Standards & Technology (NIST), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), Transportation, Dept of (DOT), Treasury, Dept of
BEYOND MEAT, INC. via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Education and outreach related to plant-based meat products.
Filing targets: SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2022 · second_quarter · Q2
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA); The Unleashing American Innovators Act; Restoring the America Invents Act; Pride in Patent Ownership Act.
Education concerning 5G wireless foundational technologies; Technology standards governance legislation; Innovation issues; United States Innovation and Competition Act (USICA); National Science Foundation (NSF) for the Future Act; National Science and Technology Strategy Act; Research Advancing to Market Production (RAMP) for Innovators Act.; National Defense Authorization Act (NDAA); Connected and Automated Vehicle Policy; America COMPETES Act.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Multiemployer pension funding legislation.
Filing targets: SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2022 · first_quarter · Q1
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799).
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2021 · fourth_quarter · 4A
Multiemployer pension funding legislation.
Filing targets: SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2021 · third_quarter · 3A
Multiemployer pension funding legislation.
Filing targets: Natl Economic Council (NEC), SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA)
Education concerning 5G wireless foundational technologies; Technology standards governance legislation; Innovation issues; United States Innovation and Competition Act (USICA); National Science Foundation (NSF) for the Future Act; National Science and Technology Strategy Act; Research Advancing to Market Production (RAMP) for Innovators Act.; National Defense Authorization Act (NDAA); Connected and Automated Vehicle Policy.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Multiemployer pension funding legislation.
Filing targets: SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2021 · fourth_quarter · Q4
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Multiemployer pension funding legislation.
Filing targets: Natl Economic Council (NEC), SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA)
Education concerning 5G wireless foundational technologies; Technology standards governance legislation; Innovation issues; Endless Frontier Act; United States Innovation and Competition Act (USICA); National Science Foundation (NSF) for the Future Act; National Science and Technology Strategy Act; Research Advancing to Market Production (RAMP) for Innovators Act.
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Science & Technology Policy (OSTP), Patent & Trademark Office (PTO), SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2021 · second_quarter · 2A
Education concerning 5G wireless foundational technologies; Technology standards governance legislation; Innovation issues; Endless Frontier Act; United States Innovation and Competition Act (USICA); National Science Foundation (NSF) for the Future Act; National Science and Technology Strategy Act; Research Advancing to Market Production (RAMP) for Innovators Act.
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA)
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
PROCARE SOFTWARE LLC via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Appropriations provisions in the proposed Build Back Better reconciliation bill regarding childcare and pre-K.
Appropriations and tax provisions in the proposed Build Back Better reconciliation bill regarding childcare and pre-K.
Tax provisions in the proposed Build Back Better reconciliation bill regarding childcare and pre-K.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2021 · third_quarter · Q3
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; H.R. 4511, FDA Advancing Collection of Transformative Science (FACTS) Act; S. 1508, A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; H.R. 4511, FDA Advancing Collection of Transformative Science (FACTS) Act; S. 1508, A bill to provide for the use of emergency use authorization data and real world evidence gathered during an emergency to support premarket applications for drugs, biological products, and devices, and for other purposes.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROCARE SOFTWARE LLC via COVINGTON & BURLING LLP
2021 · third_quarter · RR
Tax and appropriations provisions in the proposed Build Back Better reconciliation bill regarding childcare and pre-K.
Tax and appropriations provisions in the proposed Build Back Better reconciliation bill regarding childcare and pre-K.
Tax and appropriations provisions in the proposed Build Back Better reconciliation bill regarding childcare and pre-K.
RWE ALLIANCE INC. via COVINGTON & BURLING LLP
2021 · third_quarter · RR
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
Food and Drug Administration policies on real-world data and evidence in regulatory decision making.
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2021 · second_quarter · Q2
Education concerning 5G wireless foundational technologies; Technology standards governance legislation; Innovation issues; Endless Frontier Act; United States Innovation and Competition Act (USICA); National Science Foundation (NSF) for the Future Act; National Science and Technology Strategy Act; Research Advancing to Market Production (RAMP) for Innovators Act.
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA)
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2021 · second_quarter · Q2
Multiemployer pension funding legislation.
Filing targets: SENATE
QUALCOMM INCORPORATED via COVINGTON & BURLING LLP
2021 · first_quarter · Q1
Patent legislation generally; Intellectual property/antitrust issues; Diversity issues in patenting; STRONGER Patents Act; Inventor Diversity for Economic Advancement (IDEA.
Education concerning 5G wireless foundational technologies; Technology standards governance legislation; Endless Frontier Act.
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2021 · first_quarter · Q1
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2020 · fourth_quarter · Q4
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
BEYOND MEAT, INC. via COVINGTON & BURLING LLP
2020 · fourth_quarter · Q4
Education and outreach related to plant-based meat products
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2020 · third_quarter · Q3
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
BEYOND MEAT, INC. via COVINGTON & BURLING LLP
2020 · third_quarter · Q3
Education and outreach related to plant-based meat products (*Brendan Parets did not lobby the U.S. Senate*)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Pension Benefit Guaranty Corporation (PBGC), SENATE, White House Office
ROMAN HEALTH VENTURES INC. via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
Telehealth triage service related to COVID-19
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BEYOND MEAT, INC. via COVINGTON & BURLING LLP
2020 · second_quarter · Q2
Education and outreach related to plant-based meat products (*Brendan Parets did not lobby the U.S. Senate*)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROMAN HEALTH VENTURES INC. via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
Telehealth triage service related to COVID-19
Telehealth triage service related to COVID-19
Telehealth triage service related to COVID-19
MAJOR LEAGUE SOCCER, LLC (MLS) via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
United States employment visa policy; S. 386, the Fairness for High-Skilled Immigrants Act of 2019; S. Res. 461, A resolution congratulating Seattle Sounders FC on winning the 2019 Major League Soccer Cup
United States employment visa policy; S. 386, the Fairness for High-Skilled Immigrants Act of 2019
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), SENATE
BEYOND MEAT, INC. via COVINGTON & BURLING LLP
2020 · first_quarter · Q1
Education and outreach related to plant-based meat products (*Brendan Parets did not lobby the U.S. Senate*)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ROMAN HEALTH VENTURES INC. via COVINGTON & BURLING LLP
2020 · first_quarter · RR
Telehealth issues, including COVID-19 related
Telehealth issues, including COVID-19 related
Telehealth issues, including COVID-19 related
WESTERN CONFERENCE OF TEAMSTERS PENSION TRUST via COVINGTON & BURLING LLP
2019 · fourth_quarter · Q4
Multiemployer pension funding legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BYTEDANCE INC. via COVINGTON & BURLING LLP
2019 · fourth_quarter · 4T
Provide advice on technology policy issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BYTEDANCE INC. via COVINGTON & BURLING LLP
2019 · third_quarter · RA
Provide advice on technology policy issues
BYTEDANCE INC. via COVINGTON & BURLING LLP
2019 · third_quarter · Q3
Provide advice on technology policy issues. (*Clark did not lobby the U.S. Senate*)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BYTEDANCE INC. via COVINGTON & BURLING LLP
2019 · third_quarter · RR
Provide advice on technology policy issues
CHANEL, INC. via COVINGTON & BURLING LLP
2019 · second_quarter · RR
Federal cosmetic legislation
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE, State, Dept of (DOS)
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Natl Security Council (NSC), Patent & Trademark Office (PTO), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Natl Economic Council (NEC), Office of Management & Budget (OMB), Patent & Trademark Office (PTO), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Filing targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Filing targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
Telehealth triage service related to COVID-19
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Telehealth issues, including COVID-19 related